Partager

Paris, France, October 29, 2024 – AndzonBio1, the first thematic studio of the AndzonBio® initiative, has raised an initial €3M ($3.28M) in seed funding from AdBio Partners, a venture capital company builder fund specialized in early-stage investments in life sciences, and Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm) dedicated to developing innovations. This initial funding will enable the company to accelerate the most promising academic projects addressing unmet needs in cardiovascular, renal and metabolic (CVRM) disorders.

This marks a key milestone for the AndzonBio® initiative, which was launched in June 2024 through the strategic alliance between Inserm Transfert and AdBio Partners. AndzonBio1 is the first studio to emerge from this studio suite and will be dedicated to translating breakthrough academic research into therapies for patients with CVRM diseases.

AndzonBio1 has strengthened its leadership team, welcoming Loic Lhuillier, PhD as Chief Scientific Officer, Karine Charton, PhD as Chief Technology Officer, and Vincent Bischoff, PhD as Chief Operating Officer. Alongside them, a select group of top-tier advisors from the biotech and pharmaceutical industries will provide key strategic and scientific guidance, to accelerate the development of impactful therapies.

“We are delighted to co-finance this first studio with Inserm Transfert, bringing together leading biotech development experts and cutting-edge scientific projects with breakthrough potential. This perfectly aligns with AdBio Partners’ mission to support the early financing of academic innovations for the development of new therapeutic approaches. With an experienced leadership team in place, the formation of a world-leading Scientific Advisory Board, this represents a key first step for Andzobio1” said Alain Huriez, MD, Chairman & Managing Partner, AdBio Partners.

“This first studio on CVRM disorders is a major milestone of our AndzonBio® initiative and this pre-seed round of financing will greatly support the transfer and development of the most promising projects originating from Inserm research laboratories, to build a solid pipeline of CVRM therapeutic approaches for AndzonBio1” added Pascale Augé, Chairman of the Executive Management Board, Inserm Transfert.

“As AndzonBio1 begins operations, the company needs to secure the projects with the best prospects and keep abreast of new developments in the CVRM space. I am delighted to welcome and work with high-calibre experts to the AndzonBio1 SAB, who will provide invaluable knowledge and expertise to the company and support its efforts towards the identification of new treatments in an area with significant needs.” also added Loic Lhuillier, CSO, AndzonBio1.

About AdBio partners
AdBio partners is an AMF-regulated (the French financial market authority) VC firm that invests in a range of sectors within life sciences - specifically in therapeutics-oriented projects. AdBio partners’ unique strategy combines early-stage investments in promising companies and strong entrepreneurial support to strengthen the company’s growth. Created in 2016, AdBio partners has made 25 European investments in France, Belgium, and Spain with two seed-funds. AdBio partners has developed strong relationships within the European innovation ecosystem; as a result, it has attracted international VC syndicates to its portfolio companies. The operational team is composed of investment professionals
with extensive corporate experience, combined with strong scientific, medical and operational expertise.
AdBio partners

About Inserm Transfert
Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), is responsible for the value creation of innovations at Inserm and its academic partners in human health and promotes long-term technology transfers in line with international best practices. Inserm Transfert SA was founded in 2000. It manages, under a Public Service Management Contract (Délégation de Service Public), the entire promotion and transfer of knowledge emerging from the Inserm research laboratories to the industrial world, from invention disclosure to industrial partnerships and start-up incorporation. Inserm Transfert also offers services relating to setting up and managing national, European and international projects, as well as supporting the technology transfer of clinical research and health data/databases. In 2009, Inserm Transfert and Inserm established an investment fund to finance proofs of concept. In 2005, Inserm Transfert Initiative, a dedicated seed money fund for life sciences, was created. Since 2017 a pathway for pre-entrepreneurship supports researchers/inventors who aspire to become involved in entrepreneurship. In 2022, Inserm Transfert decided to become LPs in AFB Fund II to increase the opportunity of investment of seed fund in Inserm Transfert spin-off. Inserm-Transfert is at the origin of the AndzonBio® initiative.
www.inserm-transfert.fr

About AndzonBio®
AndzonBio® is an innovative biotech start-up studio suite, dedicated to accelerating the most promising scientific breakthroughs in life sciences. Launched in collaboration with AdBio Partners and Inserm Transfert, AndzonBio®’s unique model transforms cutting-edge academic research into biotech start-ups, with a focus on addressing critical unmet medical needs, each studio in a dedicated therapeutic area. Through its thematic studios, AndzonBio offers a dynamic ecosystem where scientific excellence meets strategic guidance from seasoned industry leaders and expert advisors. This approach ensures that each project receives the tailored support and resources needed to bring breakthrough therapies to patients.
www.andzonbio1.com

Press and analyst contacts
AdBio Partners
contact@adbio.partners
Inserm Transfert
communication@inserm-transfert.fr
AndzonBio
contact@andzonbio.com
AndzonBio1
contact@andzonbio1.com

Download the press release